IL13 and asthma: Tralokinumab has been recently evaluated in a trial involving 194 adult patients with moderate-to-severe uncontrolled asthma randomly assigned to receive, every 2 weeks through the subcutaneous route in addition to currently available controller therapy, either placebo or one of three different doses (150, 300, and 600 mg) of the IL-13 neutralizing antibody, respectively [80].